CDK8 Modulating Compounds for Cancer Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies lack effective CDK8 inhibitors, which are necessary for treating various diseases associated with the overexpression of CDK8, including cancers and inflammatory disorders, as CDK8 plays a crucial role in tumor regulation, immune surveillance, and signaling pathways.
Innovation Solution
Development of novel compounds, as described in Formula I, which can modulate CDK8 activity, including pharmaceutical compositions and methods for treating diseases mediated by CDK8, such as cancers and inflammatory disorders, by administering these compounds to effectively target CDK8 overexpression or aberrant activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If CDK8 inhibitors are developed to treat CDK8-overexpressing diseases, then therapeutic effectiveness is improved, but currently no FDA-approved CDK8 inhibitors exist indicating high development difficulty
Solution Approach 1:
The patent applies parameter changes by systematically modifying chemical structures of CDK8 inhibitors through variation of molecular weight, functional groups, and chemical moieties. This allows optimization of binding affinity and selectivity for CDK8, resolving the contradiction between achieving therapeutic effectiveness and overcoming development difficulty through structured chemical exploration
Solution Approach 2:
The patent segments the CDK8 inhibitor development into distinct chemical series and subclasses, each targeting specific aspects of CDK8 interaction. This segmentation enables focused optimization of different inhibitor types while maintaining overall progress toward FDA approval, addressing the complexity of developing new CDK8 inhibitors
2Reliability
If CDK8 activity is modulated to treat cancers, then tumor regulation is improved, but off-target effects on other CDK family members may occur
Solution Approach 1:
The patent applies local quality by designing CDK8 inhibitors with specific molecular features that provide selective binding to CDK8 over other CDK family members. Through careful selection of functional groups and chemical moieties, the inhibitors achieve high specificity for CDK8, minimizing off-target effects while maintaining effective tumor regulation
Solution Approach 2:
The patent uses intermediary structures in the inhibitor molecules that mediate specific interactions with CDK8. These intermediary chemical moieties act as selective mediators that facilitate binding to CDK8 while preventing interactions with other CDK members, thus reducing off-target effects
3Reliability
If CDK8 inhibitors are designed with high binding affinity, then inhibition effectiveness is improved, but compound complexity increases
Solution Approach 1:
The patent balances inhibition effectiveness and compound complexity by systematically varying parameters such as molecular weight, functional groups, and chemical moieties. This parameter optimization allows achieving high binding affinity through manageable structural modifications rather than excessive complexity
Solution Approach 2:
The patent applies partial action by designing inhibitors with just the right level of complexity needed for effective CDK8 binding. Rather than maximizing molecular complexity, the inhibitors use minimal necessary structural features to achieve high affinity, avoiding unnecessary complexity while maintaining effectiveness
Data Source
AI summary
Disclosed are compounds of Formula I:or a pharmaceutically acceptable salt, a solvate, a tautomer, an isomer or a deuterated analog thereof, wherein R4, X3, X4, X5, X6, X7 and Ring A are as described in any of the embodiments described in this disclosure; compositions thereof; and uses thereof.